Literature DB >> 20590807

Dystonia-plus syndromes.

F Asmus1, T Gasser.   

Abstract

Dystonia-plus syndromes represent a heterogeneous group of diseases, where dystonia is accompanied by other neurological features and gene mutations can be detected frequently. Symptomatic dystonias and complex neurodegenerative diseases with dystonia as part of the clinical presentation are excluded from this category. At present, the following disorders are categorized as dystonia-plus syndromes: Dopa-responsive dystonia (DRD) is a mostly pediatric-onset, neurometabolic disorder with two different modes of inheritance: in its autosomal-dominant form, heterozygous mutations of GTP-cyclohydrolase I (GCH1, DYT5) cause DRD with reduced penetrance and excellent and lasting response to levodopa. Autosomal-recessive (AR) forms of DRD are caused by homozygous or compound heterozygous mutations of the tyrosine hydroxylase (TH) or the sepiapterin reductase (SPR) gene. In AR-DRD, the phenotype is generally more severe including cognitive deficits and developmental delay. Diagnosis can be confirmed by analysis of CSF pterine metabolites. Alternatively, comprehensive genetic testing yields causative mutations in up to 80% of patients. Myoclonus-dystonia (M-D) is caused by heterozygous mutations of the epsilon-sarcoglycan gene (SGCE). Dystonia is generally only mild to moderate, and 'lightning-like' myoclonic jerks occur rarely at rest and can be triggered by complex motor tasks like writing and drawing. Both features together with an age at onset below 25 years strongly predict SGCE mutation in M-D and differentiate this genetic disease from other 'jerky' dystonias. The combination of dystonia and parkinsonism can only be rarely observed in non-degenerative syndromes. Besides DRD, two additional syndromes have been classified. Rapid-onset dystonia-parkinsonism (RPD, DYT12) is a rare disorder with an abrupt onset of symptoms over minutes to days, prominent bulbar involvement and parkinsonism with a lack of response to levodopa. Patients with this rare phenotype should be screened for mutation in the Na(+)/K(+) ATPase alpha3-subunit (ATP1A3) gene, even if family history is negative. Recently, a novel form of dystonia-parkinsonism (DYT16) has been found to be linked to mutations in the PRKRA gene, whose relation to basal ganglia disorders is yet unknown .

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20590807     DOI: 10.1111/j.1468-1331.2010.03049.x

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  16 in total

Review 1.  Diagnosis of dystonic syndromes--a new eight-question approach.

Authors:  Kelly L Bertram; David R Williams
Journal:  Nat Rev Neurol       Date:  2012-03-20       Impact factor: 42.937

Review 2.  Dystonia as a network disorder: what is the role of the cerebellum?

Authors:  C N Prudente; E J Hess; H A Jinnah
Journal:  Neuroscience       Date:  2013-12-11       Impact factor: 3.590

Review 3.  Dopa-responsive dystonia--clinical and genetic heterogeneity.

Authors:  Subhashie Wijemanne; Joseph Jankovic
Journal:  Nat Rev Neurol       Date:  2015-06-23       Impact factor: 42.937

4.  Treatment of camptocormia with continuous subcutaneous infusions of apomorphine: 1-year prospective pilot study.

Authors:  Katerina Mensikova; Michaela Kaiserova; Miroslav Vastik; Sandra Kurcova; Petr Kanovsky
Journal:  J Neural Transm (Vienna)       Date:  2014-08-19       Impact factor: 3.575

5.  Childhood dystonias.

Authors:  Samer D Tabbal
Journal:  Curr Treat Options Neurol       Date:  2015-03       Impact factor: 3.598

6.  Two novel mutations of the GTP cyclohydrolase 1 gene and genotype-phenotype correlation in Chinese Dopa-responsive dystonia patients.

Authors:  Lihua Yu; Huayong Zhou; Fayun Hu; Yanming Xu
Journal:  Eur J Hum Genet       Date:  2012-12-05       Impact factor: 4.246

7.  SPG11 Mutations Associated With a Complex Phenotype Resembling Dopa-Responsive Dystonia.

Authors:  Subhashie Wijemanne; Joshua M Shulman; Joohi Jimenez-Shahed; Daniel Curry; Joseph Jankovic
Journal:  Mov Disord Clin Pract       Date:  2015-04-28

Review 8.  Update on pediatric dystonias: etiology, epidemiology, and management.

Authors:  Emilio Fernández-Alvarez; Nardo Nardocci
Journal:  Degener Neurol Neuromuscul Dis       Date:  2012-04-11

Review 9.  ε-Sarcoglycan: Unraveling the Myoclonus-Dystonia Gene.

Authors:  Ana Cazurro-Gutiérrez; Anna Marcé-Grau; Marta Correa-Vela; Ainara Salazar; María I Vanegas; Alfons Macaya; Àlex Bayés; Belén Pérez-Dueñas
Journal:  Mol Neurobiol       Date:  2021-04-22       Impact factor: 5.590

10.  Recent advances in the molecular pathogenesis of dystonia-plus syndromes and heredodegenerative dystonias.

Authors:  Catharina Casper; Eirini Kalliolia; Thomas T Warner
Journal:  Curr Neuropharmacol       Date:  2013-01       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.